annual cash & cash equivalents:
$249.95M-$36.25M(-12.67%)Summary
- As of today (September 17, 2025), FOLD annual cash & cash equivalents is $249.95 million, with the most recent change of -$36.25 million (-12.67%) on December 31, 2024.
- During the last 3 years, FOLD annual cash & cash equivalents has fallen by -$232.55 million (-48.20%).
- FOLD annual cash & cash equivalents is now -50.42% below its all-time high of $504.15 million, reached on December 31, 2018.
Performance
FOLD Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$231.00M-$19.57M(-7.81%)Summary
- As of today (September 17, 2025), FOLD quarterly cash & cash equivalents is $231.00 million, with the most recent change of -$19.57 million (-7.81%) on June 30, 2025.
- Over the past year, FOLD quarterly cash & cash equivalents has dropped by -$29.06 million (-11.18%).
- FOLD quarterly cash & cash equivalents is now -59.87% below its all-time high of $575.66 million, reached on June 30, 2019.
Performance
FOLD quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
FOLD Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -12.7% | -11.2% |
| 3 y3 years | -48.2% | -40.3% |
| 5 y5 years | -44.8% | -25.4% |
FOLD Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -48.2% | at low | -40.3% | at low |
| 5 y | 5-year | -48.3% | at low | -58.5% | at low |
| alltime | all time | -50.4% | +3775.6% | -59.9% | +3481.8% |
FOLD Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $231.00M(-7.8%) |
| Mar 2025 | - | $250.57M(+0.3%) |
| Dec 2024 | $249.95M(-12.7%) | $249.95M(+0.1%) |
| Sep 2024 | - | $249.76M(-4.0%) |
| Jun 2024 | - | $260.06M(+8.5%) |
| Mar 2024 | - | $239.60M(-16.3%) |
| Dec 2023 | $286.20M(-2.5%) | $286.20M(+2.1%) |
| Sep 2023 | - | $280.30M(+5.5%) |
| Jun 2023 | - | $265.63M(-0.6%) |
| Mar 2023 | - | $267.11M(-9.0%) |
| Dec 2022 | $293.60M(-39.2%) | $293.60M(-17.2%) |
| Sep 2022 | - | $354.70M(-8.3%) |
| Jun 2022 | - | $386.84M(-5.9%) |
| Mar 2022 | - | $411.19M(-14.8%) |
| Dec 2021 | $482.50M(-0.2%) | $482.50M(-13.4%) |
| Sep 2021 | - | $556.96M(+45.4%) |
| Jun 2021 | - | $383.07M(-8.2%) |
| Mar 2021 | - | $417.43M(-13.6%) |
| Dec 2020 | $483.27M(+6.7%) | $483.27M(-5.1%) |
| Sep 2020 | - | $509.08M(+64.4%) |
| Jun 2020 | - | $309.59M(-8.6%) |
| Mar 2020 | - | $338.87M(-25.2%) |
| Dec 2019 | $452.74M(-10.2%) | $452.74M(-12.0%) |
| Sep 2019 | - | $514.19M(-10.7%) |
| Jun 2019 | - | $575.66M(+31.3%) |
| Mar 2019 | - | $438.33M(-13.1%) |
| Dec 2018 | $504.15M(+40.6%) | $504.15M(-10.7%) |
| Sep 2018 | - | $564.38M(+4.7%) |
| Jun 2018 | - | $538.95M(-4.2%) |
| Mar 2018 | - | $562.52M(+56.9%) |
| Dec 2017 | $358.56M(+8.5%) | $358.56M(-12.9%) |
| Sep 2017 | - | $411.52M(+81.1%) |
| Jun 2017 | - | $227.23M(-18.8%) |
| Mar 2017 | - | $279.84M(-15.3%) |
| Dec 2016 | $330.35M | $330.35M(+55.5%) |
| Sep 2016 | - | $212.40M(-0.8%) |
| Jun 2016 | - | $214.15M(+29.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2016 | - | $165.85M(-22.5%) |
| Dec 2015 | $214.03M(+41.1%) | $214.03M(-9.5%) |
| Sep 2015 | - | $236.51M(-34.6%) |
| Jun 2015 | - | $361.42M(+142.9%) |
| Mar 2015 | - | $148.77M(-1.9%) |
| Dec 2014 | $151.68M(+85.0%) | $151.68M(+78.1%) |
| Sep 2014 | - | $85.18M(+9.2%) |
| Jun 2014 | - | $78.00M(+8.9%) |
| Mar 2014 | - | $71.65M(-12.6%) |
| Dec 2013 | $82.00M(-17.3%) | $82.00M(+35.5%) |
| Sep 2013 | - | $60.49M(-18.4%) |
| Jun 2013 | - | $74.18M(-12.5%) |
| Mar 2013 | - | $84.75M(-14.5%) |
| Dec 2012 | $99.12M(+78.0%) | $99.12M(-6.7%) |
| Sep 2012 | - | $106.22M(+10.9%) |
| Jun 2012 | - | $95.77M(-11.5%) |
| Mar 2012 | - | $108.20M(+94.2%) |
| Dec 2011 | $55.70M(-48.2%) | $55.70M(-19.9%) |
| Sep 2011 | - | $69.53M(-16.3%) |
| Jun 2011 | - | $83.05M(-11.4%) |
| Mar 2011 | - | $93.77M(-12.7%) |
| Dec 2010 | $107.44M(-33.5%) | $107.44M(+86.6%) |
| Sep 2010 | - | $57.58M(-29.3%) |
| Mar 2010 | - | $81.43M(+4.1%) |
| Dec 2009 | - | $78.22M(-12.4%) |
| Sep 2009 | - | $89.27M(-11.1%) |
| Jun 2009 | - | $100.43M(-7.9%) |
| Mar 2009 | - | $109.05M(-10.0%) |
| Dec 2008 | - | $121.12M(-11.1%) |
| Sep 2008 | - | $136.25M(-6.0%) |
| Jun 2008 | - | $144.95M(-6.2%) |
| Mar 2008 | - | $154.56M(-4.3%) |
| Dec 2007 | $161.53M(+1232.0%) | $161.53M(+35.3%) |
| Sep 2007 | - | $119.41M(-5.0%) |
| Jun 2007 | - | $125.72M(+216.6%) |
| Mar 2007 | - | $39.71M(+227.4%) |
| Dec 2006 | $12.13M(+88.0%) | $12.13M(+88.0%) |
| Dec 2005 | $6.45M | $6.45M |
FAQ
- What is Amicus Therapeutics, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Amicus Therapeutics, Inc.?
- What is Amicus Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
- What is Amicus Therapeutics, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Amicus Therapeutics, Inc.?
- What is Amicus Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
What is Amicus Therapeutics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of FOLD is $249.95M
What is the all time high annual cash & cash equivalents for Amicus Therapeutics, Inc.?
Amicus Therapeutics, Inc. all-time high annual cash & cash equivalents is $504.15M
What is Amicus Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, FOLD annual cash & cash equivalents has changed by -$36.25M (-12.67%)
What is Amicus Therapeutics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of FOLD is $231.00M
What is the all time high quarterly cash & cash equivalents for Amicus Therapeutics, Inc.?
Amicus Therapeutics, Inc. all-time high quarterly cash & cash equivalents is $575.66M
What is Amicus Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, FOLD quarterly cash & cash equivalents has changed by -$29.06M (-11.18%)